BUZZ - Citi: Computershare added to the Positive Catalyst Watchlist ahead of the Annual General Meeting
路透社2026/10/26 19:56October 26 - ** Citi has added Computershare Ltd (CPU.AX) to its "Positive Catalyst Watch", anticipating the company will release positive news at its annual shareholders meeting on November 12
** The brokerage expects that Computershare will at least reiterate its target of 6% earnings growth for fiscal 2027, with a possibility of a slight upward revision
** Citi believes that, benefitting from the earlier-than-expected US interest rate hike in September and increased balances from corporate actions and debt issuance, Computershare's projected net interest income for fiscal 2027 will be slightly better than expected
** However, Citi notes that the near-term boost to earnings may be limited, as approximately 60% of the asset portfolio has already been hedged and the yield on new funds may be relatively low
** The brokerage expects the company to achieve net cash status in the first half of 2027, or have about USD 3.3 billion in debt financing capacity for acquisitions
** Citi maintains a "Neutral" rating and keeps the target price unchanged at AUD 43.20
** As of the previous trading day's close, the stock had risen 26.2% year to date
(To facilitate non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translation and provides it solely for reader convenience. Reuters assumes no responsibility for any damage or loss caused by the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-West Pharma shares rise after completing credit facility refinancing
GBP/JPY Price Forecast: Bulls eye 211.10 as bearish trend persists
CERo Therapeutics Adds UC Davis as Site for Phase 1 CER-1236 Trial in Blood Cancers